JP2025503731A5 - - Google Patents

Info

Publication number
JP2025503731A5
JP2025503731A5 JP2024542281A JP2024542281A JP2025503731A5 JP 2025503731 A5 JP2025503731 A5 JP 2025503731A5 JP 2024542281 A JP2024542281 A JP 2024542281A JP 2024542281 A JP2024542281 A JP 2024542281A JP 2025503731 A5 JP2025503731 A5 JP 2025503731A5
Authority
JP
Japan
Prior art keywords
binding domain
cancer
protein complex
terminus
complex according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503731A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/053125 external-priority patent/WO2023140950A1/en
Publication of JP2025503731A publication Critical patent/JP2025503731A/ja
Publication of JP2025503731A5 publication Critical patent/JP2025503731A5/ja
Pending legal-status Critical Current

Links

JP2024542281A 2022-01-18 2022-12-16 Ｃｄ４７／ｐｄ－ｌ１を標的とするタンパク質複合体及びその使用方法 Pending JP2025503731A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263300440P 2022-01-18 2022-01-18
US63/300,440 2022-01-18
PCT/US2022/053125 WO2023140950A1 (en) 2022-01-18 2022-12-16 Cd47/pd-l1-targeting protein complex and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025503731A JP2025503731A (ja) 2025-02-04
JP2025503731A5 true JP2025503731A5 (https=) 2025-12-23

Family

ID=87348782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542281A Pending JP2025503731A (ja) 2022-01-18 2022-12-16 Ｃｄ４７／ｐｄ－ｌ１を標的とするタンパク質複合体及びその使用方法

Country Status (10)

Country Link
US (1) US20240360219A1 (https=)
EP (1) EP4466293A4 (https=)
JP (1) JP2025503731A (https=)
KR (1) KR20240133694A (https=)
CN (1) CN118401564A (https=)
AU (1) AU2022435471A1 (https=)
CA (1) CA3239434A1 (https=)
IL (1) IL314210A (https=)
TW (1) TW202334192A (https=)
WO (1) WO2023140950A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250115658A1 (en) * 2022-01-31 2025-04-10 Fbd Biologics Limited Engineered pd-1 variants and methods of use thereof
EP4490201A4 (en) * 2023-05-31 2026-03-11 Fbd Biologics Ltd CD47/PD-L1 Targeted Protein Complex and Its Methods of Use
TW202511298A (zh) * 2023-05-31 2025-03-16 香港商Ｆｂｄ生物製劑有限公司 靶向ｃｄ４７／ｐｄ—ｌ１之蛋白質複合物及其使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011066342A2 (en) * 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CA3253628A1 (en) * 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
ES2816647T3 (es) * 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
PL3180363T3 (pl) * 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
MX2017003847A (es) * 2014-09-25 2017-12-15 Amgen Inc Proteinas biespecificas activables por proteasas.
MY202480A (en) * 2017-05-12 2024-04-30 Shanghai hengrui pharmaceutical co ltd Fusion protein containing tgf- receptor and medicinal uses thereof
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
EP3694552A1 (en) * 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
EP3710480A4 (en) * 2017-11-17 2021-12-15 Nanjing Legend Biotech Co., Ltd. SINGLE-DOMAIN ANTIBODIES AND VARIANTS OF THEM DIRECTED AGAINST PD-L1
EP3722322A4 (en) * 2017-12-04 2021-09-15 Beijing Hanmi Pharmaceutical Co., Ltd. ANTI-PD-L1 / ANTI-CD47 BISPECIFIC ANTIBODY HAVING A NATURAL ANTIBODY STRUCTURE AND IN THE FORM OF A HETERODIMER, AND ASSOCIATED PREPARATION
US20220267409A1 (en) * 2019-07-11 2022-08-25 Kahr Medical Ltd. Heterodimers and methods of use thereof
EP4038101A2 (en) * 2019-10-04 2022-08-10 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates
CA3164623A1 (en) * 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
CN113773401B (zh) * 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途

Similar Documents

Publication Publication Date Title
JP2025503731A5 (https=)
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
CN112154157B (zh) 抗ror1抗体及其用途
CN107001485B (zh) 蛋白质异二聚体及其用途
JP2021526816A (ja) Ｄｌｌ３−ｃｄ３二重特異性抗体
CN111944050A (zh) 一种抗b7-h3抗体及其应用
JP2023549537A5 (https=)
KR20230031373A (ko) 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
JP2022517920A5 (https=)
CN119233993A (zh) 用于靶向t细胞活化的cd28双特异性抗体
JP2023542900A5 (https=)
CN115894702A (zh) 一种b7h3/pdl1双特异性抗体及其药物组合物及应用
CN106831987B (zh) 一种抗人her2抗体及其编码基因和应用
CN110835372B (zh) 一种靶向Frizzled7单克隆抗体及其制备方法与应用
EP4717714A1 (en) Anti-pd-1-anti-vegf bispecific antibody, pharmaceutical composition thereof and use thereof
CN111333732B (zh) 一种靶向人bcma且激活nk细胞的双特异性抗体的制备及其应用
JP2025535104A (ja) Ｂ７ｈ３／ｐｄｌ１二重特異性抗体およびその医薬組成物ならびにその使用
JP2024503657A5 (https=)
JP2024508597A5 (https=)
RU2024123482A (ru) Белковый комплекс, нацеленный на cd47/pd-l1, и способы его использования
TW202206099A (zh) 藉由併用抗人類Fn14抗體及免疫檢查點抑制劑預防或治療癌症之醫藥組合物及方法
JPWO2016163433A1 (ja) 抗ｆｇｆｒ２抗体と他剤を含む組成物
CN115991770B (zh) 抗人gas6抗体或其抗原结合片段及其应用
CN116003599B (zh) 抗人gas6抗体或其抗原结合片段及其应用